Commercial Strategy Consulting

US-based economic consulting firm with published outcomes and cost-effectiveness analyses on esketamine treatment pathways relevant to payer decision-making and market access strategy.

Consultant Agency for Psychedelic Services (CAPS) is a UK-based advisory practice led by Dr Ben Sessa, providing consultancy for individuals, clinics, companies, and investors developing psychedelic and medical-cannabis services.

Economic and strategy consultancy with life sciences advisory services, including published analysis on the evolving psychedelic therapeutics landscape and market implications.

Delphi is a psychedelic healthcare consultancy focused on responsible integration into mainstream care. Led by Lia Mix and a cross-sector team, Delphi supports healthcare providers, investors, government agencies, and psychedelic organisations with strategy, education, and implementation guidance across regulation, delivery, and reimbursement. A major Delphi initiative is IHPI (Ibogaine Healthcare Policy Institute), a neutral, evidence-based, implementation-focused institute that develops coverage playbooks, health-economics models, and delivery blueprints for safe ibogaine adoption. Delphi also leads HOPE (Health Outcomes and Psychedelic Economics), a collaborative effort to generate independent economic evidence that can inform payer policy and broader healthcare access decisions.

Katogen is an operator-led biopharma consulting and strategy firm advising growth-stage life sciences companies, drawing on 35+ years of operator experience.

Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.

Global commercialization and market access advisory firm with published commentary on positioning psychedelic medicines within biopharmaceutical development frameworks.

UK-based psychedelic-focused consultancy offering strategic and business development services, education curriculum design, and partner collaborations for organizations in the sector.

US-based cannabis and psychedelic consulting firm providing licensing, compliance, SOP, and operational support alongside strategic planning for psychedelic ventures.

Psychedelic Alpha (Pα) is an independent, data-driven psychedelic media, research and advisory platform, founded in 2020 by Josh Hardman and based in London. It publishes the widely read weekly Psychedelic Bulletin newsletter alongside closely followed trackers of psychedelic drug development and of psychedelic law and policy, and provides advisory and consultancy services to investors, philanthropists, government agencies, startups and established firms. It is known for cutting through hype to surface what matters in the development, regulation and commercialisation of psychedelic medicines.

Purpose-led healthcare consultancy focused on integrating psychedelic-assisted therapy into health systems, with explicit services across strategic planning, implementation, reimbursement, and go-to-market execution.

Miami-based boutique consulting firm supporting cannabis and psychedelic organizations with product strategy, operational optimization, and capability development.